Related Experiment Video

Updated: May 23, 2026

Use of a Piglet Model for the Study of Anesthetic-induced Developmental Neurotoxicity (AIDN): A Translational Neuroscience Approach
06:38

Use of a Piglet Model for the Study of Anesthetic-induced Developmental Neurotoxicity (AIDN): A Translational Neuroscience Approach

Published on: June 11, 2017

Growing up with midazolam in the neonatal and pediatric intensive care

Eleonora L Swart1, Pauline R Slort, Frans B Plötz

  • 1Dept. Clinical Pharmacology and Pharmacy, VU University Medical Center, P.O. Box 7057, 1007 MB Amsterdam, The Netherlands. el.swart@vumc.nl

Current Drug Metabolism
|March 29, 2012
PubMed

Insights

Developmental changes significantly impact midazolam pharmacokinetics and pharmacodynamics in pediatric intensive care patients. Dosing requires careful consideration due to large interindividual variability and lack of high-quality evidence for continuous sedation.

Area of Science:

  • Pharmacology
  • Pediatric Intensive Care Medicine
  • Developmental Pediatrics

Background:

  • Pediatric dosing of midazolam often relies on adult extrapolations.
  • Developmental changes influence drug response in neonates and children.
  • Limited high-quality evidence supports continuous midazolam sedation in pediatric intensive care.

Purpose of the Study:

  • To review the impact of developmental changes on midazolam pharmacokinetics and pharmacodynamics in pediatric intensive care.
  • To highlight the variability in midazolam response among pediatric patients.
  • To underscore the need for better evidence in pediatric sedation.

Main Methods:

  • Review of existing studies on midazolam in neonatal and pediatric intensive care populations.
  • Analysis of pharmacokinetic alterations with increasing age.
  • Evaluation of pharmacodynamic changes related to receptor density and clinical response.

Main Results:

  • Increasing age is associated with altered midazolam pharmacokinetics, including shorter half-life and higher hepatic clearance.
  • Pharmacodynamics may change with age due to decreased receptor density, potentially reducing clinical efficacy.
  • Significant interindividual variability in response to midazolam is observed in children.

Conclusions:

  • Developmental changes in pharmacokinetics and pharmacodynamics contribute to variable midazolam responses in pediatric patients.
  • The interplay of pharmacokinetic and pharmacodynamic changes requires further investigation to determine predominant effects.
  • There is a critical need for robust evidence to guide the optimal use of midazolam for continuous sedation in pediatric intensive care settings.

More Related Videos

Anesthesia and Intubation of Preadolescent Mouse Pups for Cardiothoracic Surgery09:47

Anesthesia and Intubation of Preadolescent Mouse Pups for Cardiothoracic Surgery

Published on: June 2, 2022

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Parenteral Anesthetics: Overview01:24

Parenteral Anesthetics: Overview

Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...